Menu

Tag: drug development

ReSeqTB Data Platform Available to Public

The Rapid Drug Susceptibility Testing Consortium, coordinated by the Critical Path Institute through the Critical Path to TB Drug Regimens (CPTR) initiative, announces the public launch of the Relational Sequencing TB Data Platform (ReSeqTB). ReSeqTB is a data-sharing platform and analytic visualization tool that can be used to discover, grade, and track key bacterial drug resistance mutations. […]

January 10, 2017 Drug Development RDST Research Resources clinical trials drug development ReSeq TB

TB-PACTS Initiative Accepting Requests for Access

The TB-PACTS initiative represents a collaborative partnership between the Special Programme for Research and Training in Tropical Disease (TDR), the TB Alliance, St. George’s University of London, and Critical Path Institute (C-Path). The TB-PACTS data platform is designed to catalyze and accelerate innovative tuberculosis (TB) research by making aggregated Phase III TB clinical trial data […]

October 24, 2016 Drug Development Partner News Research Resources clinical trials drug development fluroquinolones TB-PACTS

2017 CPTR Annual Workshop to be Held March 20 – 23 in Washington DC

The 2017 Critical Path to TB Drug Regimens (CPTR) Annual Workshop, will be held March 20-23, 2017, in Washington DC. DATE: Monday, March 20 through Thursday, March 23, 2017 LOCATION: Washington, DC – Washington Marriot at Metro Center | 775 12th Street NW | 20005 Engaging panel sessions are being developed to showcase the exciting […]

October 12, 2016 Drug Development Events RDST Regulatory Science Research Resources Assay Development CPTR Workshop 2017 drug development

9th International Workshop on Pharmacology of TB Drugs – October 24th in Liverpool

The 9th edition of the International Workshop on Pharmacology of Tuberculosis Drugs will be held on 24 October 2016 in Liverpool, United Kingdom, preceding the Union World Conference on Lung Health 2016. The aim of this abstract-driven workshop is to make a significant contribution to the optimization of TB treatment, by bringing experts together and […]

October 12, 2016 Drug Development Events clinical trials drug development IUATLD Conference pharmacology

Symposium on TB ReFLECT: An integrated analysis of the fluoroquinolone TB trials – October 27, 2016 – Liverpool

On October 27th, CPTR will co-chair a symposium with the World Health Organization (WHO) at the Union World Conference on Lung Health.  This session will highlight a joint initiative by WHO and CPTR to maximize learnings from recent Phase III fluoroquinolone treatment shortening TB clinical trials through integrated meta-analysis. Presentations and panel discussion will emphasize […]

October 9, 2016 Drug Development Events drug development IUATLD Conference TB-PACTS

CPTR and SIMCYP launch models to evaluate exposure and efficacy of TB drugs in combination

The Critical Path to TB Drug Regimens (CPTR) Initiative and SIMCYP have partnered to develop a TB-specific set of models and compound files to inform the design of first-in-human trials that will simultaneously evaluate the exposure and efficacy of novel anti-TB combination regimens of up to 4 drugs. This collection of models is comprised of: […]

October 1, 2016 Drug Development Partner News clinical trials Disease-Modeling drug development

CPTR Workshop 2016: Full Content Day 4

Opening Remarks Speaker: Marco Schito, Critical Path Institute March Schito opened the last day of the CPTR 2016 Workshop recapping the progresses and challenges relating to DST development and summarizing the diagnostic development pathway. Schito shared insight on the future of DST, including the need for new policies to support the work and implementation of […]

May 3, 2016 Drug Development RDST Regulatory Science Research Resources Assay Development clinical trials CPTR Workshop 2016 drug development ReSeq TB

CPTR Workshop 2016: Full Content Day 3

Opening Remarks Speaker: Jim Gallarda, Bill & Melinda Gates Foundation Jim Gallarda set the stage for the day by considering how success in improved diagnostics should be defined, and stressing the need for innovation from both the supply (developers) side and the demand (users, uptake, and implementers) side. Gallarda emphasized that incentives are needed on […]

May 2, 2016 Drug Development RDST Regulatory Science Research Resources Assay Development clinical trials CPTR Workshop 2016 drug development ReSeq TB

CPTR Workshop 2016: Full Content Day 2

Welcoming Remarks Speaker: Mel Spigelman, TB Alliance Mel Spigelman opened the day’s program by reflecting on the changing landscape of TB drug development from a sponsor perspective. Noting that the new drugs themselves are the “beef” of the CPTR initiative, he commented that the current state of TB research has seen the retreat of some […]

May 2, 2016 Drug Development RDST Regulatory Science Research Resources Assay Development clinical trials CPTR Workshop 2016 drug development ReSeq TB

CPTR Workshop 2016: Full Content Day 1

Opening Remarks Speaker: Jan Gheuens, Bill & Melinda Gates Foundation Jan Gheuens opened CPTR’s 2016 Workshop by reminding the audience of the principles and mission of the CPTR Initiative, stressing the urgency of accelerating the development and availability of new TB combination therapies and noting the role of partnership and coordination in achieving the mission. […]

May 2, 2016 Drug Development RDST Regulatory Science Research Resources Assay Development clinical trials Community Engagement CPTR Workshop 2016 drug development